Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STATRS: Sequential Treatment Approaches for Treatment-Resistant Schizophrenia
NCT07918222Phase 3Recruiting
- Sponsor
- Shanghai Mental Health Center
- Start
- Sep 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of clozapine, aripiprazole and amisulpride in schizophrenia (5 arms), sponsored by Shanghai Mental Health Center. Primary endpoints: Positive and Negative Syndrome Scale reduction rate at Week 8 and Positive and Negative Syndrome Scale reduction rate at Week 4. Started Sep 2026; status: recruiting.
02
Drugs
clozapinearipiprazoleamisulpride
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07918222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918222.